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Piperacillin/tazobactam for nosocomial pneumonia 155515%, respectively. Gram-positive isolates were eradicated in 83% of P/T patients and
75% of IMP patients; Gram-negative pathogens were eradicated in 72% of P/T
patients and 77% of IMP patients. Treatment groups had similar number of mean
hospital days, readmission rates, and frequency of AEs. This study showed that P/T
administered four times per day was as safe and efficacious as IMP in treating
hospitalized patients with NP.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Nosocomial pneumonia (NP) is the second most
common nosocomial infection in the US and has a
significant impact on patient morbidity and mor-
tality. It is commonly estimated that NP prolongs a
patient’s hospital stay by an average of 4–9 days,
and a conservative estimate of direct costs for
excess hospitalization due to NP was $1.2 billion
per year in 1993.1 NP also is the leading cause of
death in patients with hospital-acquired infec-
tions.2,3 Estimated mortality rates range from 20%
to 50% for ventilator-acquired pneumonia (VAP)4,5
and from 30% to 75% for NP caused by Pseudomonas
aeruginosa and Acinetobacter.6 These two organ-
isms, along with Enterobacter spp., Klebsiella sp.,
Haemophilus influenzae, Staphylococcus aureus,
and Streptococcus pneumoniae, are among the
most common bacterial organisms isolated from
patients with NP in the US and Canada.2,7–10
At the time of initial diagnosis, the specific
etiology of the NP is typically unknown, making
empiric treatment with a broad-spectrum antibio-
tic a practical necessity.11 Piperacillin/tazobactam
(P/T) (Zosyn; Wyeth; Collegeville, PA, USA) is
currently approved in the US at a dose regimen of
3 g/375mg every 4 h for the treatment of NP.
Microbiologic and pharmacokinetic data suggest
that P/T should be a potentially effective antibiotic
for NP at a dose of 4 g/500mg administered every
6 h. P/T combines the broad-spectrum activity of
piperacillin with the beta-lactamase-inhibitory
properties of tazobactam and has good inhibitory
activity against Gram-negative organisms fre-
quently involved in NP, such as Haemophilus,
Enterobacter, Klebsiella, and Pseudomonas spp.,
as well as Gram-positive pathogens, including beta-
lactamase-producing strains of staphylococci and
streptococci, such as S. aureus and S. pneumoniae.
In the current study, the efficacy and safety of
4 g/500mg P/T, delivered intravenously (IV) every
6 h, was compared with that of 500mg/500mg
imipenem/cilastatin (IMP) delivered IV every 6 h,
both in combination with an aminoglycoside, to
treat patients with NP. Length of stay (LOS) and
readmission data of the two treatments were alsocompared. IMP, a member of the carbapenem class
of antibiotics, was chosen as a comparative agent
because it has a wide spectrum of activity and is
clinically effective in the treatment of hospitalized
patients with moderate to severe NP.Methods and materials
This multicenter, randomized, double-blind regis-
tration study compared the efficacy and safety of
two commonly used antibiotic treatments in com-
bination with an aminoglycoside for hospitalized
patients with acute NP in the US and Canada. The
study was designed to determine whether P/T
given IV every 6 h at a new dose of 4 g/500 g was
equivalent to IMP.
The study sample consisted of hospitalized
patients aged 18 years or older who had a diagnosis
of acute NP, as indicated by physical signs and
symptoms, fever, radiographic findings, sputum
production, and gram stain. Acute NP was defined
as pneumonia with onset of symptoms at least 48 h
after admission to an acute care hospital or chronic
care facility or no more than 7 days after discharge
from the hospital (the initial hospitalization had to
have been for at least 3 days). Patients were
excluded if they had hypotension, hypersensitivity
to the study drugs, chronic respiratory disease, or
renal insufficiency. Patients with central nervous
system disease were also excluded from the study
because of the seizure potential of imipenem.
All patients who received at least one dose of
study drug comprised the intent-to-treat (ITT)
population. To be considered efficacy evaluable
(EE), a patient had to (a) have a baseline pathogen
susceptible to both IMP and P/T, (b) receive the
study drug for at least 5 days (or be declared a
therapeutic failure after eight doses), (c) receive
no more than one dose of a concomitant systemic
antibiotic for NP after baseline culture (unless
declared a therapeutic failure), and (d) complete
the test-of-cure visit 14 (77) days after disconti-
nuing the study drug.
A computer-generated randomization schedule
assigned patients in a 1:1 ratio to receive either
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(40–60min) IV infusion every 6 h. Treatment con-
tinued for at least 5 days but not more than 21
days. In addition, all patients received tobramycin
(5mg/kg/day, open-label) until the identity of the
baseline pathogen was determined. Patients from
whom P. aeruginosa was isolated at baseline
continued to receive tobramycin (or amikacin) for
the duration of treatment.Assessment procedures
On study days 1 through 21 (or last day of
treatment), vital signs and signs and symptoms of
intercurrent illness were evaluated. Blood cultures
were obtained on day 1 and repeated periodically
until a negative result was obtained. Chest radio-
graphs and specimens from the lower respiratory
tract were collected on day 4 and the last day of
treatment. Signs and symptoms of NP were
assessed on study days 1 through 7, then every
3–4 days during treatment and on the last day of
treatment. If the patient was declared a
clinical failure after 8 or more doses of the
study drug, he or she was considered a failure for
the rest of the trial. The duration of therapy was
based on resolution of clinical signs and symptoms
such as: presence and severity of respiratory
secretion production, the predominant character-
istics of respiratory secretions, the presence of
abnormal temperature, resolution of infiltrates on
the chest X-ray, decrease in WBC counts and the
use of mechanical ventilation and supplemental
oxygen.
Patients were assessed twice after discontinuing
the study drug. The first assessment took place on
posttreatment day 2 (71 day) and was followed by
a test-of-cure assessment 14 (77) days after the
last dose of study drug. At both times, patients’
clinical signs and symptoms of NP were evaluated,
respiratory specimens were collected (if available),
and blood cultures were obtained if signs of active
infection were evident. Patient records were
maintained throughout the study period to monitor
the level of care delivered and to record con-
current nonpharmacologic procedures, including
mechanical ventilation.Efficacy and safety analyses
Efficacy analyses compared the effects of the two
treatments on rates of clinical cure (versus failure)
and rates of eradication (versus persistence,
relapse, and superinfection). The primary efficacy
endpoint was the clinical response in the EEpopulation at the test-of-cure visit, although the
tables herein show clinical results for the ITT
population as well. In addition, because mechanical
ventilation is suggestive of the severity of the NP,
cure rates of P/T and IMP patients were compared
separately for patients who were on a ventilator at
baseline and those who were not. Clinical cure
rates were also analyzed separately for patients
with monomicrobial infections versus those with
polymicrobial infections. Secondary endpoints were
eradication rates at both the patient and pathogen
level. At the pathogen level, eradication rates were
analyzed overall and separately by type of baseline
isolate. A summary of clinical and microbiological
endpoints appears in Table 1.
In addition, the LOS in the hospital and ICU and
readmission rates were also analyzed. The LOS in
the hospital was calculated in two ways. The first
measured from the recorded hospital admission
date to the date of discharge; the second measured
from the date on which the study drug was initiated
to the date of discharge.
All ITT patients were included in the safety
analysis. Safety assessments consisted of the
physical examinations and tests described above
as well as routine urinalysis and hematology tests.
Exposure to study drug and adverse events (AEs)
were recorded throughout the study period.Statistics and sample size
All statistical tests were two-sided and measured at
the 0.05 level of significance. Drug equivalence was
evaluated using 95% confidence intervals (CI), with
correction for continuity. Sample size was esti-
mated using the assumption that P/T and IMP
treatments would be equally effective in producing
clinical cure rates of 70% at test-of-cure. A sample
of 108 EE patients per treatment group would
ensure, with 86% probability, that the upper and
lower bounds of a 95% confidence limit for the true
difference in efficacy did not exceed 20%. In
addition, cure rates and eradication rates were
compared using the Cochran–Mantel–Haenszel
procedure.
To evaluate differences in LOS in the hospital,
results were summarized by using Kaplan–Meier
survival estimates and analyzed with the log-rank
test. The percentages of patients who were
readmitted to the hospital were compared
by the Fisher exact test. Similarly, safety assess-
ments used the Fisher exact test to compare
percentages of AEs occurring in the P/T and IMP
groups.
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Table 1 Summary of efficacy evaluation clinical and microbiological endpoints.
I. Clinical responses
A. Cure
1. Patient completed treatment, and
2. Did not require further antibacterial treatment to treat acute NP, and
3. Had improvement or lacked progression on chest radiograph, and
4. Showed recovery from the acute infection
B. Failure
1. Patient did not respond during treatment and required nonstudy antibiotic, or
2. Initially recovered but deteriorated by time of follow-up, requiring further antibiotic therapy, or
3. Died because of pneumonia
C. Indeterminate
1. Patient failed to have an outcome determination, or
2. Withdrew from treatment less than 48 h after initiation of therapy, or
3. Received concomitant antibiotics for reasons other than failure, or
4. Died during therapy for noninfection related reason
II. Microbiological responses at the patient level
A. Eradication
1. No pathogens were present in repeat lower respiratory tract culture, or
2. Patient’s clinical outcome of cure precluded availability of a specimen for culture
B. Persistence
1. Baseline pathogen was present in repeat lower respiratory tract culture, or
2. Patient received nonstudy antibiotic therapy, or
3. Patient received study drug for more than 21 days to treat lung infection
C. Relapse: baseline pathogen was absent at repeat lower respiratory tract culture but reappeared at follow-
up, along with signs and symptoms of pneumonia
D. Indeterminate
1. Patient received concomitant antibiotics for reasons other than failure, or
2. Failed to have an outcome determination, or
3. Withdrew from treatment less than 48 h after initiation of therapy, or
4. Died during therapy for noninfection-related reason
E. Superinfection
1. New pathogen(s) emerged during treatment, requiring nonstudy antibiotic, and
2. Clinical and laboratory evidence showed emergence or exacerbation of infection
III. Microbiological responses at the pathogen level
A. Eradication
1. Baseline pathogen was not present in repeat lower respiratory tract culture, or
2. Patient’s clinical outcome of cure precluded availability of a specimen for culture
B. Persistence
1. Baseline pathogen was present in repeat lower respiratory tract culture, or
2. Patient had a clinical outcome of failure, and culture data were not available
C. Indeterminate
1. Culture data were not available for the baseline pathogen
Piperacillin/tazobactam for nosocomial pneumonia 1557
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Forty investigators at 66 sites in the US and Canada
conducted the study over a period of 56 months,
from April 1997 to December 2001. All sites
received approvals from their independent review
boards, and all patients or their families provided
written informed consent to participate.
From a total of 449 enrollees, 437 patients
received at least one dose of study drug and were
thus considered the ITT population. Within this
population, 222 patients received P/T and 215
received IMP. Approximately 45% of the patients
(n ¼ 197) met the criteria for being EE; of these, 98
received P/T and 99 received IMP. Reasons for not
being EE were essentially the same in each
treatment arm (Fig. 1). A comparable number of
patients received o5 days of treatment. The most
common reasons for discontinuation were clinical
failures and protocol violations. A small number of
patients were discontinued due to occurrence of
AEs. Four patients in the P/T group and five449 Patients E
and Random
437 Patients 
(ITT Popula
222 Treated
with P/T
45 (20%) received nonstudy antibiotics
18 (8%) did not have baseline pathogen
14 (6%) received P/T < 5 days
11 (5%) were not assessed at test-of-cure
36 (16%) did not meet inclusion criteria
98 Evaluable 
Patients (44.1%)
213 
Pathogens
Figure 1 Disposition of patients in comparative studpatients in the IMP group died during the first 4
days of treatment. Of these, four in the P/T group
and three in the IMP group had received p8 doses
of the study drugs. The remaining two patients in
the IMP group who died in the first 4 days of
treatment and had at least eight doses of study
drug were considered failures. Although the treat-
ment arms had similar demographic characteristics
in most respects, there were significantly more
men and higher body weights in the P/T group than
in the IMP group (Po0:01) (Table 2).
On average, tobramycin was administered for 6
days in 91% of EE patients receiving P/T and 88% of
EE patients receiving IMP (Table 3). When used in
combination with tobramycin, P/T and IMP were
administered for similar lengths of time.
Clinical outcomes
The study’s primary efficacy endpoint was the cure
rate in EE patients at the test-of-cure visit. The
overall clinical cure rate was 68% in P/T patients andanrolled
ized
Treated
tion)
215 Treated
with IMP
53 (25%) received nonstudy antibiotics
18 (8%) did not have baseline pathogen
13 (6%) received IMP < 5 days
5 (2%) were not assessed at test-of-cure
27 (13%) did not meet inclusion criteria
99 Evaluable 
Patients (46.0%)
180 
Pathogens
y of P/T and IMP to treat nosocomial pneumonia.
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Table 2 Demographic and disease/treatment characteristics at baseline.
Characteristic Efficacy evaluable patients Intent-to-treat patients
P/T (n ¼ 98) IMP (n ¼ 99) P/T (n ¼ 222) IMP (n ¼ 215)
Age in years, mean (SD) 52.2 (19.1) 52.4 (20.7) 53.2 (19.1) 52.7 (20.9)
Male/female (%)y 80/20 60/40 78/22 64/36
Ethnicity (%)
White 78 76 81 80
Black 18 18 14 14
Hispanic 2 1 1 1
Asian 0 1 o1 o1
Other 2 4 3 3
Weight (kg), mean (SD)z 82.0 (19.4) 75.1 (17.4) 81.2 (17.9) 76.8 (16.8)
Where NP acquired (%)
Hospital 93 96 91 95
Long-term care facility 7 4 9 5
APACHE II score, mean 14.0 13.1 13.9 13.0
Ventilated at baseline (%) 77 74 71 67
P/T ¼ piperacillin/tazobactam; IMP ¼ imipenem/cilastatin; APACHE ¼ Acute Physiology and Chronic Health Evaluation.
Between-group differences are not significant unless otherwise noted.
yPo0:01 by the Fisher exact test.
zPo0:01 by ANOVA with treatment as a factor.
Table 3 Patient exposure to study drug and tobramycin.
Patient population P/T only P/T plus
tobramycin
IMP only IMP plus
tobramycin
Mean exposures
Efficacy evaluable patients, n (%) 9 (9.2) 89 (90.8) 12 (12.1) 87 (87.9)
Duration of tobramycin, in days — 6.1 — 6.0
Duration of study drug, in days 8.9 10.2 10.5 10.6
Total number of doses of study drug 31.4 35.8 37.6 37.2
Peak serum tobramycin
concentration (mg/l)
— 5.36 — 5.90
Intent-to-treat patients 25 (11.3) 197 (88.7) 28 (13.0) 187 (87.0)
Duration of tobramycin, in days — 5.5 — 5.6
Duration of study drug, in days 7.6 9.4 9.3 9.7
Total number of doses of study drug 25.9 32.9 32.7 33.9
Peak serum tobramycin
concentration (mg/l)
— 1.21 — 1.37
P/T ¼ piperacillin/tazobactam; IMP ¼ imipenem/cilastatin.
Piperacillin/tazobactam for nosocomial pneumonia 155961% in IMP patients in the EE population (Table 4).
This difference was not statistically significant.
As expected, clinical cure rates were higher
among patients who were not on mechanical
ventilation at baseline; in the EE population, 83%
of P/T patients and 69% of IMP patients were
considered cured after treatment with the study
drug. However, about three-quarters of the EE
patients in both groups were on ventilators.
Ventilator patients in the P/T group had a curerate of 64%, compared with 58% in the IMP group.
The differences were not statistically significant.
Finally, when stratified by mono- and polymicro-
bial infections, clinical cure rates were better in
patients with more than one pathogen than in those
with a single pathogen. For example, among P/T
patients in the EE population, 71% of those with
polymicrobial infections were cured versus 64% of
those with a monomicrobial infection. Among
counterpart IMP patients, 64% with polymicrobial
ARTICLE IN PRESS
Table 4 Clinical cure rates at test-of-cure visit.
Patient population P/T n/total (%) IMP n/total (%) Difference in cure (95% CI) P-value
Group/subgroup
Efficacy evaluable patients
Total 67/98 (68.4) 60/99 (60.6) 0.078 (0.066, 0.221) 0.256
Ventilated at baseline 48/75 (64.0) 42/73 (57.5) 0.065 (0.106, 0.235) 0.422
Not ventilated 19/23 (82.6) 18/26 (69.2) 0.134 (0.143, 0.410) 0.282
Monomicrobial 25/39 (64.1) 30/52 (57.7) 0.064 (0.160, 0.288) 0.538
Polymicrobial 42/59 (71.2) 30/47 (63.8) 0.074 (0.125, 0.272) 0.422
Intent-to-treat patients
Total 121/222 (54.5) 111/215 (51.6) 0.029 (0.069, 0.127) 0.547y
Ventilated at baseline 81/157 (51.6) 68/143 (47.6) 0.040 (0.079, 0.160) 0.485y
Not ventilated 40/65 (61.5) 43/72 (59.7) 0.018 (0.160, 0.197) 0.829y
Monomicrobial 38/84 (45.2) 45/93 (48.4) 0.031 (0.190, 0.127) 0.676y
Polymicrobial 62/101 (61.4) 52/94 (55.3) 0.061 (0.088, 0.209) 0.392y
P/T ¼ piperacillin/tazobactam; IMP ¼ imipenem/cilastatin; CI ¼ confidence interval.
Cure versus failure, by Cochran–Mantel–Haenszel test.
yCure versus failure/indeterminate, by Cochran–Mantel–Haenszel test.
100.0%
80.0%
60.0%
40.0%
20.0%
0.0%
All P/T All IMP P/T with 1
Pathogen
P/T with >1
Pathogen
IMP with 1
Pathogen
IMP with >1
Pathogen
Superinfection Relapsed Persistent Eradicated
Figure 2 Microbiological response rates at the patient level in the efficacy evaluable population at the test-of-cure
visit: *No significant differences between P/T-IMP pairs by Cochran-Mantel-Haenszel test.
M. Joshi et al.1560infections were cured versus 58% of IMP patients
with a monomicrobial infection. Overall, more than
half of the patients had more than one pathogen,
although polymicrobial infections were observed
more frequently in the P/T group (60%) than in the
IMP group (47%).Microbiological outcomes
Microbiological response rates were comparable
among EE patients treated with P/T and those
treated with IMP (Fig. 2). Excluding one indetermi-
nate response in the P/T group, pathogens were
eradicated in 62 of 97 P/T patients and 58 of 99 IMPpatients (P ¼ 0:445; 95% CI, 0.093, 0.200). As
with clinical cure rates, eradication rates were
slightly higher among patients with more than
one pathogen than in those with monomicrobial
infections.
A total of 393 pathogens were isolated at
baseline (Table 5). Eradication rates were higher
at the pathogen level than at the patient level in
both EE treatment groups. At this level of analysis,
the study drugs appeared equally effective: 75% of
pathogens were eradicated in P/T patients, and
76% were eradicated in IMP patients. The most
frequently occurring Gram-positive pathogen was
S. aureus (n ¼ 67), and the most frequently
occurring Gram-negative isolates were H. influen-
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Table 5 Eradication of baseline pathogens in EE population at test-of-cure.
Pathogen Total P/T IMP
Total isolates eradicated, n/total (%) 297/393 (75.6) 160/213 (75.1) 137/180 (76.1)
Gram-positive isolates 92/117 (78.6) 48/58 (82.8) 44/59 (74.6)
Staphylococcus aureus 47/67 (70.1) 24/31 (77.4) 23/36 (59.0)
Streptococcus pneumoniae 11/13 (84.6) 6/7 (85.7) 5/6 (83.3)
Other Streptococcus sp. 19/20 (95.0) 10/10 (100.0) 9/10 (90.0)
Other Gram-positive isolates 15/17 (88.0) 8/10 (80.0) 7/7 (100.0)
Gram-negative isolates 205/276 (74.3) 112/155 (72.3) 93/121 (76.9)
Acinetobacter baumanii 13/17 (76.5) 7/9 (77.8) 6/8 (75.0)
Enterobacter aerogenes 6/13 (46.2) 3/8 (37.5) 3/5 (60.0)
Enterobacter cloacae 16/23 (69.6) 8/14 (57.1) 8/9 (88.9)
Escherichia coli 13/15 (86.7) 4/5 (80.0) 9/10 (90.0)
Haemophilus influenzae 40/47 (85.1) 24/29 (82.8) 16/18 (88.9)
Klebsiella pneumoniae 18/26 (69.2) 12/14 (85.7) 6/12 (50.0)
Klebsiella oxytoca 10/10 (100.0) 7/7 (100.0) 3/3 (100.0)
Proteus mirabilis 7/9 (77.8) 4/6 (66.7) 3/3 (100.0)
Pseudomonas aeruginosa 25/35 (71.4) 13/18 (72.2) 12/17 (70.6)
Serratia marcescens 11/17 (64.7) 4/9 (44.4) 7/8 (87.5)
Stenotrophomonas maltophilia 4/9 (44.4) 2/5 (40.0) 2/4 (50.0)
Other Gram-negative isolates 42/55 (76.5) 24/31 (77.4) 18/24 (75.0)
EE ¼ efficacy evaluable; P/T ¼ piperacillin/tazobactam; IMP ¼ imipenem/cilastatin.
Some patients had infections involving more than one pathogen.
Piperacillin/tazobactam for nosocomial pneumonia 1561zae (n ¼ 47), P. aeruginosa (n ¼ 35), and
K. pneumoniae (n ¼ 26). Gram-positive isolates
were eradicated in 83% of P/T patients and 75% of
IMP patients, whereas Gram-negative pathogens
were eradicated in 72% of P/T patients and 77% of
IMP patients.
The clinical and microbiologic outcomes were
compared for all pathogens and it was found that
the number of bacterial eradications correlated
well with the number of clinical cures, although
there were some discrepancies in findings for three
isolates: S. aureus, K. pneumoniae, and E. aero-
genes. (Fig. 3). In the S. aureus subgroup, eight of
31 in the P/T group and 20 of 36 in the IMP patients
were considered clinical failures, and six of the
eight clinical failures in the P/T group and 12 of the
20 clinical failures in the IMP group were also
microbiologic failures. The correlative findings for
infections with K. pneumoniae appeared to be
similar, although the numbers were smaller. In the
Enterobacter subgroup, a greater number of
patients failed clinically and microbiologically in
the P/T group (Fig. 3).LOS and readmission rates
P/T and IMP patients had similar hospital and ICU
LOS. As calculated from the time of admission todischarge, the mean hospital LOS for EE patients
was approximately 3 weeks, while mean LOS in an
intensive care unit was approximately 16 days.
Hospital readmission rates in both groups were
small and were not significantly different.Safety
One or more treatment-emergent adverse events
(TEAEs) were reported during the study by 92% of
ITT patients (204/222 P/T patients; 198/215 IMP
patients). As Table 6 illustrates, the most fre-
quently reported TEAEs were diarrhea (22%) and
agitation (16%). Both occurred more often in P/T
patients, but the differences between groups were
not statistically significant. The other common
TEAEs were peripheral edema, local reaction to
injection, vomiting, and rash, which occurred with
similar frequency in each group (approximately
14%). Significantly (Po0:050) more P/T patients
had thrombocythemia (12% versus 7%) and respira-
tory disorder (4% versus 1%), while significantly
(Po0:050) more IMP patients reported insomnia
(10% versus 4%), constipation (14% versus 8%), and
headache (10% versus 4%).
Adverse events led 39 patients (25 P/T, 14 IMP,
P ¼ 0:094) to discontinue from the study. This
group included 32 patients who died before the
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Table 6 Number (%) of patients with TEAEs of incidence X10% in at least one treatment group.
Body system/adverse event P/T IMP Total Fisher’s exact P-value
Diarrhea 56 (25) 39 (18) 95 (22) 0.082
Agitation 39 (18) 32 (15) 71 (16) 0.517
Peripheral edema 31 (14) 33 (15) 64 (15) 0.688
Local reaction to injection 35 (16) 29 (14) 64 (15) 0.589
Vomiting 26 (12) 36 (17) 62 (14) 0.170
Rash 26 (12) 34 (16) 60 (14) 0.266
Constipation 17 (8) 31 (14) 48 (11) 0.031
Nausea 18 (8) 25 (12) 43 (10) 0.261
Fever 18 (8) 23 (11) 41 (9) 0.413
Thrombocythemia 27 (12) 14 (7) 41 (9) 0.049
Anemia 22 (10) 12 (6) 34 (8) 0.108
Headache 10 (5) 21 (10) 31 (7) 0.040
Insomnia 8 (4) 21 (10) 29 (7) 0.012
Indicates statistical significance.
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Figure 3 Relationship between clinical observations of cure and failure versus bacteriologic endpoints of eradication
(E) and persistence (P) of selected isolates: S. aureus, K. pneumoniae, and E. aerogenes.
Clinical failures
S. aureus
P/T: 8 of 31 total patients; 2 of 24 eradication group and 6 of 7 persistence group;
IMP: 20 of 36 total patients; 8 of 23 eradication group and 12 of 13 persistence group.
K. pneumoniae
P/T: 2 of 14 total patients; 1 of 12 eradication group and 1 or 2 persistence group;
IMP: 6 of 12 total patients; 1 of 6 eradication group and 5 of 6 persistence group.
E. aerogenes
P/T: 4 of 8 total patients; 0 of 3 eradication group and 4 of 5 persistence group;
IMP: 2 of 5 total patients; 0 of 3 eradication group and 2 of 2 persistence group.
M. Joshi et al.1562treatment period ended. In all, 40 patients died: 23
(10%) P/T patients and 17 (8%) IMP patients
(P ¼ 0:41). The causes of death were similar ineach group. In the P/T group, no deaths were
considered to be related to the study drug. Two
deaths in the IMP group were considered possibly
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result of superinfection, and the second died from
toxic dilation of the colon. Serious adverse events
(SAEs) occurred in 83 patients, 42 (19%) in the P/T
group and 41 (19%) in the IMP group.Discussion
NP is a serious infection that requires early and
appropriate therapy. Often at the time of initial
diagnosis, the causative agents of NP are unknown.
Thus, in choosing an antibiotic, clinicians need to
consider the most likely pathogens for NP and VAP,
the local nosocomial infection patterns, and the
antibiotic’s spectrum of coverage.12 Moreover, the
choice should also take into consideration that
some antimicrobial agents are more likely than
others to promote resistance. It is often recom-
mended that clinicians begin treatment of NP with
a broad-spectrum agent, which later may be
followed by narrow-spectrum therapy once an
infectious pathogen is identified.3,13,14 Recent
recommendations for empiric treatment of noso-
comial infections have included P/T, the carbape-
nems, and cefepime all in combination with
quinolones or aminoglycosides.10,15,16
At least four randomized trials have also found
P/T to be at least as effective as comparator
antibiotics in treating serious infections in
hospitalized patients. One was a hospital formulary
study, which found equivalent rates of curing or
improving serious infections in hospitalized pa-
tients (70% of P/T patients and 68% of IMP
patients).17 The second, a multicenter ICU study
of patients with VAP, found that P/T+amikacin had
a clinical and bacteriologic cure rate (51%) at least
equivalent to that of ceftazidime+amikacin (36%)
(95% CI, 0.2, 30.2).18 The third, a multicenter
open-label study, showed a 70% clinical success rate
in NP patients treated with P/T+tobramycin versus
a 50% success rate in patients treated with
ceftazidime+tobramycin (P ¼ 0:006).11 Jaccard et
al. compared P/T to IMP in patients with NP and
reported failures of 13/75 (17%) in the P/T group,
and 23/79 (29%) in the IMP-group. For infections
due to P. aeruginosa, 2/21 (10%) failed in the P/T
group compared with 12/24 (50%) in the IMP
group.19
Several studies have also evaluated the role of
IMP in the treatment of NP. Zanetti et al. reported
that cefepime and IMP had comparable clinical and
microbiologic efficacy. Cefepime was less active
against extended spectrum beta-lactamase (ESBL)-
producing organisms, but primary and secondaryresistance to IMP was more common in P. aerugi-
nosa.20
In the year 2000, in a select group of bronchoalveo-
lar lavage (BAL)-confirmed VAP, Torres et al. reported
that ciprofloxacin and IMP were equally effective.
However in the P. aeruginosa subgroup , there was a
trend towards decreased eradication rates with IMP
(ciprofloxacin 7/14 (50%); IMP 3/12 (25%).21
Because P/T and IMP are active against a variety
of Gram-negative and Gram-positive pathogens,
they have a potentially important role to play in
the treatment of NP infections. The pathogens most
frequently isolated in this study—S. aureus, Hae-
mophilus spp., P. aeruginosa, Klebsiella spp.,
Enterobacter spp., and Acinetobacter sp.—are
typical of patients with NP in the US and Canada.
Results of this study showed that an IV treatment
regimen of 4 g/500mg P/T was as clinically and
microbiologically effective in treating such infec-
tions as an IV regimen of 500mg/500mg IMP (both
administered every 6 h in combination with an
aminoglycoside).
As anticipated, the clinical cure rates for the
whole group correlated with the microbiological
eradications. However, for individual pathogens
such as S. aureus, clinical cure rates were higher
in the P/T group and, unlike the IMP group,
correlated well with the microbiological eradica-
tion. Because both P/T and IMP have good activity
against the methicillin-sensitive strains of
S. aureus, we are at a loss to explain this result;
however, we do recommend that future studies
address this issue. Although the numbers of
patients were small, higher clinical cure rates were
seen with P/T in the Klebsiella group. A study by
Pillay et al. showed equal efficacy of P/T and IMP in
neonates with K. pneumoniae infection.22 Rhom-
berg et al. provided the antimicrobial susceptibility
rates in the year 2003 against all Gram-negative
rods (GNR) tested. About 90.2% were susceptible to
the P/T group and 95.6% were susceptible to the
IMP group. IMP was uniformly active (100%) and P/T
inhibited 84.9% of ESBL-producing GNR isolates.23
An explanation for improved response to P/T could
be that this study excluded all resistant pathogens
at study entry; therefore, the ESBL-producing
Klebsiella species were not included in the study.
In the Enterobacter subgroup, IMP performed
better. Johnson et al. reported that P/T exhibited
modest activity against those strains which hyper-
express amp c enzymes including Enterobacter sp.
(68.8% susceptible or intermediate). Carbapenems
were the most active agents against such species.24
This may explain the higher success rate with
imipenem. In both of these subgroups, clinical cure
rates correlated with microbiologic eradication.
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led to similar ICU and hospital LOS and that both
drugs were generally well tolerated among patients
with NP. Data from the 1997 to 2000 SENTRY
Antimicrobial Surveillance Program confirm that
P/T and IMP are among the most active broad-
spectrum antimicrobial agents against P. aerugino-
sa worldwide.25 Thus it is not surprising that both
P/T and IMP are used as standard treatment for
serious infections in hospitalized patients.
Studies in the US and Europe have found that
overuse of IMP has been linked to antibiotic
resistance to other carbapenems and beta-lactams.
In an observational study by Rahal et al. a hospital’s
decision to restrict cephalosporin use because of
Klebsiella resistance led to a 140% increase in the
prescription of IMP, which was accompanied by a
69% increase in IMP-resistant P. aeruginosa26; simi-
larly, an earlier study in the same setting suggested
that increased use of IMP was associated with an
outbreak of IMP-resistant Acinetobacter baumannii.27
Other studies have found that use of IMP in hospital
settings was significantly associated with increases in
P. aeruginosa that were resistant not only to IMP but
also to other antipseudomonal agents,28,29 including
P/T and ceftazidime.30 In addition, third-generation
cephalosporins have been linked with the emergence
of extended-spectrum beta-lactamase-producing or-
ganisms31 and vancomycin-resistant enterococci in-
fections.32 One study also demonstrated that for
isolation of resistant Enterobacter, the risk conferred
by P/T was similar to that conferred by third
generation cephalosporins.33 Other studies, however,
suggest that P/T sustains its potent activity against
hospital infections while resistance to other anti-
biotics has emerged.34,35
Inadequate initial antibiotic treatment of noso-
comial infections has been linked to increased
patient morbidity and mortality and to the emer-
gence of antibiotic resistance.13 Thus, the initial
choice of therapy is fundamentally important not
only for patients currently ill with NP but also for
the continued usefulness of antibiotics for nosoco-
mial infections in the near future.36 The results of
the current study support the choice of P/T at a
dose of 4 g/500 g given IV every 6 h for patients with
NP, including VAP.Conclusion
The current study shows that IV administration of
4 g/500mg of P/T every 6 h is efficacious in the
treatment of hospitalized patients with NP. The
study demonstrated that several pathogens typi-cally involved in NP were susceptible to P/T, and
P/T displayed a wide spectrum of activity against
Gram-positive and Gram-negative isolates. The
positive results of this study warrant further
investigation in clinical trials powered to test the
superiority of P/T as empiric therapy for NP and to
test the use of P/T to treat other serious
nosocomial infections.Acknowledgment
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